Leading Interventional Cardiologists to Discuss CorPath® System’s Role in Physician Radiation Reduction and Procedural Precision in Complex and Radial PCI at TCT 2015

Corindus Vascular Robotics to showcase capabilities of CorPath System

Waltham, MA – October 5, 2015 – Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS] announced today that renowned interventional cardiologists will highlight their use of the CorPath System through presentations and poster sessions during the upcoming TCT 2015 meeting, Oct. 11-15, in San Francisco. Physicians will present their experience using the CorPath System during PCI procedures to demonstrate the radiation reduction that it provides.

Corindus Vascular Robotics, Inc. will showcase the System’s capabilities during complex PCI procedures and highlight recent studies pertaining to occupational hazards and robotic precision at booth #1525.

Presentations as part of the scientific program include:

- "Initial Clinical Experience Performing Robotic Percutaneous Coronary Intervention from the Radial Approach," Dr. Joseph Sheets, Spectrum Healthcare, Thursday, Oct. 15, 12:30 p.m. Moscone South, Lower Level, Room 104.

Abstract poster sessions include:

- "RAPID (Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease) Study," featuring the findings of Drs. Ehtisham Mahmud, Florian Schmid, Peter Kalmar, Hannes Duetschmann and Marianne Brodmann.
- "Longitudinal Geographic Miss (LGM) in Robotic-Assisted versus Manual Percutaneous Coronary Interventions," featuring the findings of Drs. Emile Mehanna, Hiram Bezerra, Christopher Metzger, Ronald Caputo, Juan F Granada, George W. Vetrovec and Giora Weisz.
- "Feasibility of Robotic Percutaneous Coronary Intervention for Unprotected Left Main Stenosis in the Presence and Absence of Left Ventricular Hemodynamic Support with Impella," featuring the findings of Drs. Ehtisham Mahmud, Arturo Dominguez, John Bahadorani, Mitul Patel and Ryan Reeves.
- "Robotically Assisted Unprotected Left Main PCI with Impella Support," featuring the findings of Drs. John Bahadorani, Ehtisham Mahmud, and Arturo Dominguez.

All poster sessions occur on Tuesday, Oct. 14, 4-6 p.m.

"Robotic technology is changing the way we perform PCIs in the cath lab by enabling enhanced visualization and precision while offering enhanced radiation protection, which is especially important as procedures become longer and more complex," said Dr. Mahmud, Chief of Cardiovascular Medicine, Director of Sulpizio Cardiovascular Center-Medicine, and Director of Interventional Cardiology at UC San Diego Health System. "TCT provides an ideal venue for those of us who have adopted the technology to share our experiences with other interventionalists."

"The peer to peer education of advanced robotic complex PCI at TCT is an important step in the process of clinical expansion and awareness of the CorPath System's capabilities. We are looking forward to a very productive
conference as we provide the best procedure solution for the growing concern of occupational hazards in the cath lab,” said David Handler, President and CEO of Corindus. "Use of the CorPath System in the cath lab continues to grow and our users continue to successfully use robotic-assistance to treat patients during complex PCI procedures."

The CorPath System is the first FDA-approved medical device to bring robotic precision and accuracy to help optimize clinical outcomes during coronary angioplasties. Additionally, the CorPath System reduces radiation exposure for the interventional cardiologist by approximately 95%, according to the 2012 PRECISE Study.**

TCT Meeting attendees can register here to schedule a demo of complex robotic-assisted PCI with the CorPath System at the Corindus Vascular Robotics Booth #1525.

**About Corindus Vascular Robotics, Inc.**

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The Company’s FDA-cleared CorPath System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through of improper stent placement with manual PCI procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program.” For additional information, visit www.corindus.com, and follow @CorindusInc.

* CorPath is intended for use in the remote delivery and manipulation of coronary guidewires and balloon/stent catheters during PCI procedures.

**PRECISE Study was sponsored by Corindus, Inc.

Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus' control. Examples of such statements include statements regarding the potential benefits of our CorPath System and robotic-assisted PCI for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. More information on potential factors that could affect Corindus’ financial results is included from time to time in the “Forward Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Corindus’ periodic and current filings with the SEC, as well as those discussed under the “Risk Factors” and “Forward-Looking Statements” section of Corindus’ Annual Report on Form 10-K filed with the SEC on March 30, 2015 and available on Corindus’ website at http://www.corindus.com/about-corindus/investor-relations. Forward-looking statements speak only as of the date they are made and Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, that occur after that date.

# # #

**Media Contact:**

Yuliya Kutuzava
corindus@knbcomm.com
(203) 504-8230 ext. 131